CBS 2019
CBSMD教育中心
中 文

血管内超声指导

Abstract

Recommended Article

Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies In-stent neoatherosclerosis: a final common pathway of late stent failure Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement The Year in Cardiovascular Medicine 2020: Imaging: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of imaging are Fausto Pinto, José Luis Zamorano and Chiara Bucciarelli-Ducci. Judy Ozkan speaks with them The effect of complete percutaneous revascularisation with and without intravascular ultrasound guidance in the drugeluting stent era Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry Optical coherence tomography and intravascular ultrasound assessment of the anatomic size and wall thickness of a muscle bridge segment A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis

Original ResearchVolume 74, Issue 13 Supplement, October 2019

JOURNAL:J Am Coll Cardiol. Article Link

Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial

JJ Zhang, XF Gao, the ULTIMATE Investigators. Keywords: IVUS guidance vs angiography guidance; TVF; CKD

ABSTRACT


BACKGROUND - Patients with chronic kidney disease (CKD) present more frequently with complex and extensive lesions, and intravascular ultrasound (IVUS)–guided drug-eluting stent (DES) implantation is associated with improved clinical outcomes in complex lesions. However, it still remains controversial that routine IVUS guidance could be beneficial to CKD patients.


METHODS - This study aimed to investigate the impact of IVUS- or angiography-guided DES implantation on patients with CKD based on the database from the ULTIMATE trial.


RESULTS - Estimated glomerular filtration rate (eGFR) was available in 1,443 patients, with mean eGFR 81.41 ± 28.92 ml/min/1.73 m2, of whom 723 were in the IVUS guidance group and 720 in the angiography guidance group. Finally, CKD was present in 349 (24.2%) patients. At 12 months, the target vessel failure (TVF) in the CKD group was 7.2%, significantly higher than 3.2% in the no CKD group (hazard ratio [HR]: 2.30; 95% CI: 1.38 to 3.84; p = 0.001), mainly driven by increased risk of cardiac death (2.9% vs. 0.5%; p < 0.001) in CKD patients. Moreover, there were 25 TVFs in CKD patients, with 7 (3.9%) in the IVUS group and 18 (10.7%) in the angiography group (HR: 0.35; 95% CI: 0.15 to 0.84; p = 0.01) (Figure), while 35 TVFs occurred in patients without CKD, with 14 (2.6%) in the IVUS group and 21 (3.8%) in the angiography group (HR: 0.67; 95% CI: 0.34 to 1.32; p = 0.25; p for interaction = 0.24). The reduced risk of TVF in the IVUS group for CKD patients was mainly driven by the lower risk of TVMI (0.6% vs. 3.6%; borderline p = 0.05) and TVR (1.1% vs. 4.7; p = 0.04).


CONCLUSION - The present study demonstrated that CKD patients undergoing DES implantation had a higher risk of TVF during 12 months of follow-up. More importantly, the risk of TVF in CKD patients could be significantly decreased through IVUS guidance compared with angiography guidance.